ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells
and slow the growth of head and neck cancer.
PURPOSE: Phase II trial to study the effectiveness of ZD1839 in treating patients who have
metastatic or recurrent cancer of the head and neck.